Jaffetilchin Investment Partners Has Boosted Stanley Black & Decker (SWK) Stake By $407,628; 1 Analysts Are Bullish Vascular Biogenics Ltd. (VBLT) Last Week

Vascular Biogenics Ltd. (NASDAQ:VBLT) Logo

Among 5 analysts covering Vascular Biogenics (NASDAQ:VBLT), 1 have Buy rating, 0 Sell and 4 Hold. Therefore 20% are positive. Vascular Biogenics had 18 analyst reports since August 24, 2015 according to SRatingsIntel. The firm has “Hold” rating by Piper Jaffray given on Thursday, March 8. On Monday, September 21 the stock rating was upgraded by JMP Securities to “Mkt Outperform”. The stock of Vascular Biogenics Ltd. (NASDAQ:VBLT) has “Buy” rating given on Friday, October 23 by Chardan Capital Markets. The stock of Vascular Biogenics Ltd. (NASDAQ:VBLT) has “Buy” rating given on Monday, September 28 by Roth Capital. The rating was maintained by H.C. Wainwright with “Buy” on Tuesday, November 7. The firm has “Hold” rating given on Thursday, March 8 by JMP Securities. On Thursday, March 22 the stock rating was maintained by H.C. Wainwright with “Hold”. The stock of Vascular Biogenics Ltd. (NASDAQ:VBLT) earned “Buy” rating by H.C. Wainwright on Tuesday, June 28. The firm earned “Neutral” rating on Friday, March 9 by Chardan Capital Markets. The stock has “Buy” rating by Chardan Capital Markets on Monday, September 21. See Vascular Biogenics Ltd. (NASDAQ:VBLT) latest ratings:

22/03/2018 Broker: H.C. Wainwright Rating: Hold New Target: $3.0 Maintain
09/03/2018 Broker: Chardan Capital Markets Old Rating: Buy New Rating: Neutral Downgrade
08/03/2018 Broker: JMP Securities Rating: Hold Downgrade
08/03/2018 Broker: Piper Jaffray Rating: Hold Downgrade
08/03/2018 Broker: H.C. Wainwright Old Rating: Buy New Rating: Neutral Old Target: $11 Downgrade
07/11/2017 Broker: H.C. Wainwright Rating: Buy New Target: $11.0 Maintain
30/10/2017 Broker: Chardan Capital Markets Rating: Buy New Target: $20.0
03/10/2017 Broker: H.C. Wainwright Rating: Buy New Target: $11.0 Maintain

Jaffetilchin Investment Partners Llc increased Stanley Black & Decker Inc (SWK) stake by 126.81% reported in 2017Q4 SEC filing. Jaffetilchin Investment Partners Llc acquired 2,412 shares as Stanley Black & Decker Inc (SWK)’s stock declined 8.99%. The Jaffetilchin Investment Partners Llc holds 4,314 shares with $732,000 value, up from 1,902 last quarter. Stanley Black & Decker Inc now has $23.61B valuation. The stock increased 1.56% or $2.36 during the last trading session, reaching $153.2. About 1.06 million shares traded. Stanley Black & Decker, Inc. (NYSE:SWK) has risen 16.50% since March 31, 2017 and is uptrending. It has outperformed by 4.95% the S&P500.

Since October 25, 2017, it had 0 insider buys, and 4 sales for $14.43 million activity. 4,182 shares were sold by VOELKER JOSEPH R, worth $681,300. $11.41M worth of Stanley Black & Decker, Inc. (NYSE:SWK) was sold by LOREE JAMES M on Monday, October 30. On Wednesday, October 25 the insider Ansell Jeffrey D sold $1.84 million.

Among 25 analysts covering Stanley Black & Decker (NYSE:SWK), 20 have Buy rating, 0 Sell and 5 Hold. Therefore 80% are positive. Stanley Black & Decker has $204.0 highest and $67 lowest target. $163.90’s average target is 6.98% above currents $153.2 stock price. Stanley Black & Decker had 58 analyst reports since August 3, 2015 according to SRatingsIntel. Morgan Stanley maintained the shares of SWK in report on Monday, March 12 with “Overweight” rating. The company was maintained on Tuesday, July 25 by Morgan Stanley. The rating was upgraded by JP Morgan to “Overweight” on Monday, April 24. The rating was maintained by KeyBanc Capital Markets with “Buy” on Friday, November 17. The rating was upgraded by KeyCorp to “Overweight” on Monday, April 24. The company was initiated on Thursday, September 17 by UBS. The company was maintained on Wednesday, October 18 by Wells Fargo. JP Morgan maintained Stanley Black & Decker, Inc. (NYSE:SWK) on Monday, October 30 with “Overweight” rating. The stock of Stanley Black & Decker, Inc. (NYSE:SWK) has “Hold” rating given on Friday, October 13 by KeyBanc Capital Markets. The rating was maintained by Imperial Capital on Friday, October 23 with “In-Line”.

Investors sentiment decreased to 1.03 in 2017 Q4. Its down 0.07, from 1.1 in 2017Q3. It fall, as 35 investors sold SWK shares while 229 reduced holdings. 89 funds opened positions while 182 raised stakes. 125.92 million shares or 0.99% less from 127.17 million shares in 2017Q3 were reported. Alliancebernstein L P, New York-based fund reported 502,904 shares. Columbus Circle owns 0.84% invested in Stanley Black & Decker, Inc. (NYSE:SWK) for 259,303 shares. 16,133 were accumulated by Amica Pension Fund Board Of Trustees. Orrstown Fincl Services Inc invested in 500 shares or 0.1% of the stock. Quantitative Invest Mngmt Ltd Limited Liability Company invested in 44,000 shares or 0.11% of the stock. Missouri-based Comm Fincl Bank has invested 0.01% in Stanley Black & Decker, Inc. (NYSE:SWK). Koch Industries Incorporated holds 0.07% or 2,927 shares in its portfolio. Neuberger Berman Grp Incorporated Limited Liability Co accumulated 1.34 million shares or 0.26% of the stock. Asset Mgmt One Ltd holds 0.1% in Stanley Black & Decker, Inc. (NYSE:SWK) or 255,529 shares. 3 were accumulated by Benjamin F Edwards Com. Hartford Fin Mngmt holds 0.33% or 3,931 shares. Livforsakringsbolaget Skandia Omsesidigt holds 0.04% or 2,352 shares. Honeywell holds 1.04% or 186,200 shares. Brown Advisory Securities Ltd Liability Company owns 1,537 shares or 0.05% of their US portfolio. Moreover, First Fincl In has 0.04% invested in Stanley Black & Decker, Inc. (NYSE:SWK).

Jaffetilchin Investment Partners Llc decreased Jpmorgan Chase & Co (NYSE:JPM) stake by 9,381 shares to 4,149 valued at $444,000 in 2017Q4. It also reduced First Tr Morningstar Div Lea (FDL) stake by 194,605 shares and now owns 368,768 shares. Ishares Tr (IJR) was reduced too.

It closed at $2.3 lastly. It is down 59.29% since March 31, 2017 and is downtrending. It has underperformed by 70.84% the S&P500.

Vascular Biogenics Ltd., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of treatments for cancer. The company has market cap of $68.76 million. The companyÂ’s program is based on its proprietary vascular targeting system platform technology, which utilizes genetically targeted therapy to destroy newly formed or angiogenic blood vessels. It currently has negative earnings. The Company’s lead product candidate is VB-111, a gene biologic that is in Phase III clinical trials for the treatment of recurrent glioblastoma, an aggressive form of brain cancer; and has completed Phase II clinical trials for recurrent platinum-resistant ovarian cancer, as well as for iodine-resistant differentiated thyroid cancer.

Stanley Black & Decker, Inc. (NYSE:SWK) Institutional Positions Chart